Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aceragen, Inc.ACGN · Entity 110652 | Director | August 10, 2023 | August 11, 2023 |
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director | June 04, 2026 | June 08, 2026 |
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 05, 2020 | June 09, 2020 |
| Merus N.V.MRUS · Entity 70740 | Director | December 12, 2025 | December 12, 2025 |
| Passage BIO, Inc.PASG · Entity 7829 | Director | May 19, 2026 | May 21, 2026 |
| TREVENA INCTRVN · Entity 85383 | Director | May 13, 2020 | May 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aceragen, Inc.
Report date August 10, 2023 · Filed August 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2023-08-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-08-10 · Sale · Disposed 51 · Balance 0 F1: Shares of common stock held in the name Brian Macdonald for Maxine Gowen Trust, for which the Reporting Person is a beneficiary and trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock held in the name Brian Macdonald for Maxine Gowen Trust, for which the Reporting Person is a beneficiary and trustee.
Aclaris Therapeutics, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,334 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Exercise / conversion · Acquired 11,580 · Balance 33,334 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.71 · Expires 2036-06-03 | Direct | 42,350 |
Reported balance
After 2026-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-04 · Grant · Acquired 42,350 · Balance 42,350 F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,987 |
Reported balance
After 2026-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-04 · Grant · Acquired 10,987 · Balance 10,987 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-05 · Exercise / conversion · Disposed 11,580 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5: The shares underlying these restricted stock units vested on June 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.
F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
F5: The shares underlying these restricted stock units vested on June 5, 2026.
Akebia Therapeutics, Inc.
Report date June 05, 2020 · Filed June 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,133 |
Ending reported balance
After 2020-06-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-06-05 · Grant · Acquired 13,700 · Balance 28,700 F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Row 2 · 2020-06-08 · Sale · Disposed 4,567 · Balance 24,133 F2: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of 100% of the Reporting Person's restricted stock units granted on June 6, 2019. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.96 · Expires 2030-06-05 | Direct | 20,100 |
Reported balance
After 2020-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-05 · Grant · Acquired 20,100 · Balance 20,100 F3: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
F2: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of 100% of the Reporting Person's restricted stock units granted on June 6, 2019.
F3: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
Merus N.V.
Report date December 12, 2025 · Filed December 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.60 · Expires 2035-05-22 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Disposition to issuer · Disposed 13,193 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.73 · Expires 2034-05-07 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-12 · Disposition to issuer · Disposed 8,844 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.29 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-12 · Disposition to issuer · Disposed 14,414 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.56 · Expires 2032-05-31 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-12 · Disposition to issuer · Disposed 16,604 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2031-05-28 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-12 · Disposition to issuer · Disposed 12,240 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.06 · Expires 2030-10-23 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-12 · Disposition to issuer · Disposed 7,957 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.
F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Passage BIO, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2036-05-19 | Direct | 10,539 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 10,539 · Balance 10,539 F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.
TREVENA INC
Report date May 13, 2020 · Filed May 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2030-05-13 | Direct | 64,103 |
Reported balance
After 2020-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-13 · Grant · Acquired 64,103 · Balance 64,103 F1: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2020 Filed May 19, 2020 19:07 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001179110-20-006349 · edgar.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2030-05-12 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2020 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on May 12, 2021 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:23 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 4,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016076 · doc4.xml · derivative · entry 3 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:23 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 4,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016076 · doc4.xml · derivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,438 Underlying: Common Stock · 4,438 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:23 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 4,438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016076 · doc4.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:47 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock option (right to buy) · Derivative | 16,000 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001209191-19-041175 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-07-01 F1 · shares: This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy. F2 · derivative.exercise_date: The shares subject to this stock option will vest in thirty-six (36) equal monthly installments commencing on the one-month anniversary of July 2, 2019, subject to the reporting person's continuous service through each vesting date. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001562180-19-003436 · primarydocument.xml · derivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2029-06-06 F2 · shares: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003436 · primarydocument.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 16:06 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001179110-19-007278 · edgar.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2029-06-04 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2019 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on June 4, 2020 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document |
| May 16, 2019 Filed May 16, 2019 21:31 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001209191-19-030520 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:59 UTC | TREVENA INC TRVN · Entity 85383 | PurchaseCommon Stock | 50,000 | $1.02 | $51,000.00 |
DisclosureSEC source: 0001209191-19-007388 · doc4.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.01 - $1.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.direct: 50,000 of these shares are held jointly with the reporting person's spouse. The reporting person disclaims beneficial ownership of the shares held by her spouse, and this report should not be deemed an admission that the reporting person is the beneficial owner of her spouse's shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 16:01 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Options · Derivative | 50,000 | $1.53 Strike: $1.53 | $76,500.00 |
DisclosureSEC source: 0001179110-18-008941 · edgar.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-06-20 F1 · security: These options were granted pursuant to the Company's director compensation on the date of the Company's 2018 annual meeting of stockholders at an exercise price to the closing price of the Company's common stock on the date of grant. F2 · derivative.exercise_date: These options will vest in full and become immediately exercisable on the first anniversary of the date of grant, subject to continued service as director, and are granted under the Company's 2013 Stock Incentive Plan, as amended. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 12:16 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 12,500 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001562180-18-003016 · primarydocument.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-06-14 F1 · shares: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:20 UTC | TREVENA INC TRVN · Entity 85383 | GrantEmployee Stock Option (Right to Buy) · Derivative | 252,500 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-18-015840 · doc4.xml · derivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,500 Underlying: Common Stock · 252,500 shares Expires 2028-02-28 F2 · derivative.exercise_date: The option shall vest and become exercisable on an annual basis (every twelve months) from the Transaction Date listed above, with respect to one-half of the total number of shares subject to the option, in each case subject to the reporting person's Continuous Service (as defined in the 2013 Equity Incentive Plan, as amended) as of each such vesting date. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:20 UTC | TREVENA INC TRVN · Entity 85383 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-18-015840 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-02-28 F1 · derivative.exercise_date: The option shall vest and become exercisable with respect to one-sixteenth of the total number of shares subject to the option on a quarterly basis (every three months) from the Transaction Date listed above, subject to the reporting person's Continuous Service (as defined in the Trevena, Inc. 2013 Equity Incentive Plan, as amended) as of each such vesting date. Read SEC document |
| August 28, 2017 Filed Aug 29, 2017 20:43 UTC | TREVENA INC TRVN · Entity 85383 | GrantEmployee Stock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001209191-17-050602 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2027-08-28 F1 · derivative.exercise_date: The option shall vest and become exercisable with respect to one-sixteenth of the total number of shares subject to the option on a quarterly basis (every three months) from the Transaction Date listed above, subject to the reporting person's Continuous Service (as defined in the Trevena, Inc. 2013 Equity Incentive Plan, as amended) as of each such vesting date. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 12,500 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001562180-17-002291 · primarydocument.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-15 F1 · derivative.exercise_date: 100% of the option shares vest on the first anniversary of the date of grant (the "Vesting Date"), provided that the Reporting Person remains in continuous service as a member of the Issuer's Board of Directors through the Vesting Date, and provided further that the options held by the Reporting Person shall be eligible for vesting acceleration upon a "Change in Control" as defined and provided for in the Issuer's Non-Employee Director Stock Option Award Agreement. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 16:16 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001179110-17-008810 · edgar.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-07 F1 · security: These options were granted pursuant to the Company's director compensation on the date of the Company's 2017 annual meeting of stockholders at an exercise price to the closing price of the Company's common stock on the date of grant. F2 · derivative.exercise_date: These options will vest in full and become immediately exercisable on the first anniversary of the date of grant, subject to continued service as director, and are granted under the Company's 2013 Stock Incentive Plan, as amended. Read SEC document |
| May 25, 2017 Filed Jun 9, 2017 21:57 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 403 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038965 · doc4.xml · nonDerivative · entry 12 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 195,512 F5 · kind: This transaction involved a gift of securities by the reporting person to the Brian MacDonald Irrevocable Trust. F6 · ownership.nature: These shares are held by the Brian MacDonald Irrevocable Trust. The reporting person's spouse is the beneficiary and the Trustee of the Brian MacDonald Irrevocable Trust. The reporting person disclaims beneficial ownership of the shares held by the Brian MacDonald Irrevocable Trust, and this report should not be deemed an admission that the reporting person is the beneficial owner of her children's shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 25, 2017 Filed Jun 9, 2017 21:57 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 403 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038965 · doc4.xml · nonDerivative · entry 11 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F5 · kind: This transaction involved a gift of securities by the reporting person to the Brian MacDonald Irrevocable Trust. Read SEC document |
| March 16, 2017 Filed Jun 9, 2017 21:57 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038965 · doc4.xml · nonDerivative · entry 10 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 216,500 F4 · kind: This transaction involved a gift of securities by the reporting person to the Maxine Gowen Irrevocable Trust. F3 · ownership.nature: These shares are held by the Maxine Gowen Irrevocable Trust. The reporting person is the beneficiary and the Trustee of the Maxine Gowen Irrevocable Trust. Read SEC document |
| March 16, 2017 Filed Jun 9, 2017 21:57 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038965 · doc4.xml · nonDerivative · entry 9 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,403 F4 · kind: This transaction involved a gift of securities by the reporting person to the Maxine Gowen Irrevocable Trust. Read SEC document |
| March 13, 2017 Filed Jun 9, 2017 21:57 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038965 · doc4.xml · nonDerivative · entry 8 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 195,109 F5 · kind: This transaction involved a gift of securities by the reporting person to the Brian MacDonald Irrevocable Trust. F6 · ownership.nature: These shares are held by the Brian MacDonald Irrevocable Trust. The reporting person's spouse is the beneficiary and the Trustee of the Brian MacDonald Irrevocable Trust. The reporting person disclaims beneficial ownership of the shares held by the Brian MacDonald Irrevocable Trust, and this report should not be deemed an admission that the reporting person is the beneficial owner of her children's shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| March 13, 2017 Filed Jun 9, 2017 21:57 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038965 · doc4.xml · nonDerivative · entry 7 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,403 F5 · kind: This transaction involved a gift of securities by the reporting person to the Brian MacDonald Irrevocable Trust. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 21:56 UTC | TREVENA INC TRVN · Entity 85383 | GrantEmployee Stock Option (Right to Buy) · Derivative | 303,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001209191-17-017687 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,000 Underlying: Common Stock · 303,000 shares Expires 2027-03-02 F1 · derivative.exercise_date: The option shall vest and become exercisable with respect to one-fourth of the total number of shares subject to the option on each of March 2, 2018, March 2, 2019, March 2, 2020 and March 2, 2021, subject to the reporting person's Continuous Service (as defined in the Trevena, Inc. 2013 Equity Incentive Plan, as amended) as of each such vesting date. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 13:34 UTC | TREVENA INC TRVN · Entity 85383 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 106,329 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001209191-17-014568 · doc4.xml · derivative · entry 5 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,329 shares Expires 2020-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 13:34 UTC | TREVENA INC TRVN · Entity 85383 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,074 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001209191-17-014568 · doc4.xml · derivative · entry 4 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,074 shares Expires 2021-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 13:34 UTC | TREVENA INC TRVN · Entity 85383 | Exercise / conversionCommon Stock | 110,403 | $0.68 | $75,294.85 |
DisclosureSEC source: 0001209191-17-014568 · doc4.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2017 Filed Jun 9, 2017 21:57 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038965 · doc4.xml · nonDerivative · entry 6 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 145,109 F5 · kind: This transaction involved a gift of securities by the reporting person to the Brian MacDonald Irrevocable Trust. F6 · ownership.nature: These shares are held by the Brian MacDonald Irrevocable Trust. The reporting person's spouse is the beneficiary and the Trustee of the Brian MacDonald Irrevocable Trust. The reporting person disclaims beneficial ownership of the shares held by the Brian MacDonald Irrevocable Trust, and this report should not be deemed an admission that the reporting person is the beneficial owner of her children's shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 23, 2017 Filed Jun 9, 2017 21:57 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038965 · doc4.xml · nonDerivative · entry 5 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,403 F5 · kind: This transaction involved a gift of securities by the reporting person to the Brian MacDonald Irrevocable Trust. Read SEC document |
| January 23, 2017 Filed Jun 9, 2017 21:57 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038965 · doc4.xml · nonDerivative · entry 4 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 156,500 F4 · kind: This transaction involved a gift of securities by the reporting person to the Maxine Gowen Irrevocable Trust. F3 · ownership.nature: These shares are held by the Maxine Gowen Irrevocable Trust. The reporting person is the beneficiary and the Trustee of the Maxine Gowen Irrevocable Trust. Read SEC document |
| January 23, 2017 Filed Jun 9, 2017 21:57 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038965 · doc4.xml · nonDerivative · entry 3 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,403 F4 · kind: This transaction involved a gift of securities by the reporting person to the Maxine Gowen Irrevocable Trust. Read SEC document |
| January 06, 2017 Filed Jan 6, 2017 21:42 UTC | TREVENA INC TRVN · Entity 85383 | GrantEmployee Stock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001209191-17-002668 · doc4.xml · derivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-01-06 F1 · derivative.exercise_date: The option shall vest and become exercisable with respect to one-fourth of the total number of shares subject to the option on each of January 6, 2018, January 6, 2019, January 6, 2020 and January 6, 2021, subject to the reporting person's Continuous Service (as defined in the Trevena, Inc. 2013 Equity Incentive Plan, as amended) as of each such vesting date. Read SEC document |
| January 06, 2017 Filed Jun 9, 2017 21:57 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038965 · doc4.xml · nonDerivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 150,000 F1 · kind: This transaction involved a gift of securities by the reporting person's spouse to the Maxine Gowen Irrevocable Trust. F3 · ownership.nature: These shares are held by the Maxine Gowen Irrevocable Trust. The reporting person is the beneficiary and the Trustee of the Maxine Gowen Irrevocable Trust. Read SEC document |
| January 06, 2017 Filed Jun 9, 2017 21:57 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038965 · doc4.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 4,000 F1 · kind: This transaction involved a gift of securities by the reporting person's spouse to the Maxine Gowen Irrevocable Trust. F2 · ownership.nature: These shares are held by the reporting person's spouse. The reporting person disclaims beneficial ownership of the shares held by her spouse, and this report should not be deemed an admission that the reporting person is the beneficial owner of her spouse's shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 16:29 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 7,000 | $1.50 | $10,500.00 |
DisclosureSEC source: 0001179110-17-000514 · edgar.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,543 F1 · kind: This stock was issued to the reporting person pursuant to her election under the Issuer's director compensation program in lieu of cash. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 22:37 UTC | TREVENA INC TRVN · Entity 85383 | PurchaseCommon Stock | 12,500 | $4.10 | $51,250.00 |
DisclosureSEC source: 0001209191-16-149122 · doc4.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.08 - $4.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| October 20, 2016 Filed Oct 25, 2016 21:28 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 4,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146893 · doc4.xml · nonDerivative · entry 4 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 139,109 F3 · kind: This transaction involved a gift of securities by the reporting person to the Brian MacDonald Irrevocable Trust. F4 · ownership.nature: These shares are held by the Brian MacDonald Irrevocable Trust. The reporting person's spouse is the beneficiary and the Trustee of the Brian MacDonald Irrevocable Trust. The reporting person disclaims beneficial ownership of the shares held by the Brian MacDonald Irrevocable Trust, and this report should not be deemed an admission that the reporting person is the beneficial owner of her children's shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 20, 2016 Filed Oct 25, 2016 21:28 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 4,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146893 · doc4.xml · nonDerivative · entry 3 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F3 · kind: This transaction involved a gift of securities by the reporting person to the Brian MacDonald Irrevocable Trust. Read SEC document |
| October 20, 2016 Filed Oct 25, 2016 21:28 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146893 · doc4.xml · nonDerivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 154,000 F1 · kind: This transaction involved a gift of securities by the reporting person to her spouse. F2 · ownership.nature: These shares are held by the reporting person's spouse. The reporting person disclaims beneficial ownership of the shares held by her spouse, and this report should not be deemed an admission that the reporting person is the beneficial owner of her spouse's shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 20, 2016 Filed Oct 25, 2016 21:28 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146893 · doc4.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,084 F1 · kind: This transaction involved a gift of securities by the reporting person to her spouse. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:43 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146367 · doc4.xml · nonDerivative · entry 6 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 144,000 F1 · kind: This transaction involved a gift of securities by the reporting person to her spouse. F2 · ownership.nature: These shares are held by the reporting person's spouse. The reporting person disclaims beneficial ownership of the shares held by her spouse, and this report should not be deemed an admission that the reporting person is the beneficial owner of her spouse's shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:43 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146367 · doc4.xml · nonDerivative · entry 5 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,084 F1 · kind: This transaction involved a gift of securities by the reporting person to her spouse. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:43 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 135,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146367 · doc4.xml · nonDerivative · entry 4 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 135,025 F3 · kind: This transaction involved a gift of securities by the reporting person to the Brian MacDonald Irrevocable Trust. F4 · ownership.nature: These shares are held by the Brian MacDonald Irrevocable Trust. The reporting person's spouse is the beneficiary and the Trustee of the Brian MacDonald Irrevocable Trust. The reporting person disclaims beneficial ownership of the shares held by the Brian MacDonald Irrevocable Trust, and this report should not be deemed an admission that the reporting person is the beneficial owner of her children's shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:43 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 135,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146367 · doc4.xml · nonDerivative · entry 3 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,084 F3 · kind: This transaction involved a gift of securities by the reporting person to the Brian MacDonald Irrevocable Trust. Read SEC document |
| October 16, 2016 Filed Jun 9, 2017 16:15 UTC | Aceragen, Inc. IDRA · Entity 110652 | GiftCommon Stock | 10,542 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-008807 · edgar.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 16:52 UTC | Aceragen, Inc. IDRA · Entity 110652 | PurchaseCommon Stock | 4,102 | $2.56 | $10,501.12 |
DisclosureSEC source: 0001179110-16-030454 · edgar.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,543 F1 · kind: This stock was issued to the reporting person pursuant to her election under the Issuer's director compensation program in lieu of cash. Read SEC document |
| September 29, 2016 Filed Oct 19, 2016 20:43 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 130,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146367 · doc4.xml · nonDerivative · entry 2 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 134,000 F1 · kind: This transaction involved a gift of securities by the reporting person to her spouse. F2 · ownership.nature: These shares are held by the reporting person's spouse. The reporting person disclaims beneficial ownership of the shares held by her spouse, and this report should not be deemed an admission that the reporting person is the beneficial owner of her spouse's shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 29, 2016 Filed Oct 19, 2016 20:43 UTC | TREVENA INC TRVN · Entity 85383 | GiftCommon Stock | 130,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146367 · doc4.xml · nonDerivative · entry 1 GOWEN MAXINE · CIK 0001280044 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,109 F1 · kind: This transaction involved a gift of securities by the reporting person to her spouse. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.